Clinical Management of Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a systemic autoimmune disorder characterised by persistent synovial inflammation, cartilage degradation and bone erosion. Early diagnosis and prompt initiation of therapy are critical to prevent irreversible joint damage and preserve function. Clinical management revolves around a treat-to-target strategy, aiming for sustained remission or low disease activity through regular assessment of symptoms, biomarkers and imaging findings. Conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), notably methotrexate, remain first-line therapy, often combined with short-term glucocorticoids to control acute flares. For patients with insufficient response, biologic DMARDs (bDMARDs) targeting tumour-necrosis factor, interleukin-6 or B cells are added, followed by targeted synthetic DMARDs (tsDMARDs) such as Janus kinase (JAK) inhibitors for further optimisation. Multidisciplinary care, patient education and shared decision-making form the cornerstone of modern RA management, enabling individualised regimens that balance efficacy, safety and quality of life.

Research from Nature Portfolio

Recent studies have revealed unprecedented heterogeneity within the inflamed synovium. Using multi-modal single-cell profiling, researchers have categorised synovial tissues into discrete cell-type abundance phenotypes (CTAPs). These CTAPs range from lymphocyte-rich to stromal-dominated patterns and correlate with distinct cytokine milieus, histological features and clinical responses. This atlas paves the way for phenotypic stratification of patients and the design of precision therapies aimed at the dominant pathogenic cell states in each subgroup. Earlier foundational work has identified specialised subsets of synovial fibroblasts that drive chronic inflammation and matrix destruction. One perivascular subset, marked by podoplanin, THY1 and cadherin-11 but lacking CD34, exhibits invasive behaviour and pro-inflammatory cytokine production, offering a novel stromal target for future intervention.

Clinical Management of Rheumatoid Arthritis publication trend

The graph below shows the total number of articles in clinical management of rheumatoid arthritis across all publications each year (not limited to Nature Index journals).

Technical terms

Conventional synthetic DMARDs (csDMARDs): Small-molecule agents that modulate immune activity and slow joint damage, exemplified by methotrexate.

Biologic DMARDs (bDMARDs): Protein-based therapies targeting specific cytokines or cell surface markers to interrupt inflammatory cascades.

Targeted synthetic DMARDs (tsDMARDs): Small-molecule inhibitors designed to interfere with particular intracellular signalling enzymes, such as JAKs.

Synovium: The specialised lining of joint capsules that becomes inflamed and hyperplastic in RA.

Cell-type abundance phenotypes (CTAPs): Classifications of synovial tissue based on dominant immune or stromal cell populations.

Fibroblast subsets: Distinct populations of stromal cells within the synovium with specialised roles in inflammation and tissue remodelling.

Treat-to-target: A management approach that adjusts therapy at regular intervals to reach predefined remission or low-activity goals.

References

1. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduction and Targeted Therapy (2023).
2. Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes. Nature (2023).
3. Management of Rheumatoid Arthritis: An Overview. Cells (2021).
4. Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis. Nature Communications (2018).
5. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology (2018).